Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,167 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | unknown | Phase 2 | 120 | Hunan Cancer HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03608007 | X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement | unknown | Phase 2 | 69 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2020 | clinicaltrials |
| NCT03624309 | Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer | unknown | Phase 2 | 84 | Hunan Cancer HospitalOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT04192682 | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04213170 | Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04213937 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 386 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04211896 | Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | unknown | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Dec 26, 2019 | clinicaltrials |
| NCT04201990 | Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer(CCA-MPLC) | unknown | Phase 1 / Phase 2 | 20 | ShiYue LiOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02364076 | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | unknown | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04193007 | The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC(BRATR) | unknown | Phase 2 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04189094 | Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC | unknown | Phase 2 | 140 | Zhejiang Cancer HospitalOTHER | 0 | Dec 6, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT03700359 | A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC | unknown | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04181372 | A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer | unknown | Phase 2 | 50 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04180501 | SRS Sequential Sindilimab in Brain Metastasis of NSLSC | unknown | Phase 2 | 25 | Xiaorong DongOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04167774 | A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC(Compass-001) | unknown | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04164745 | Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer | unknown | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT04001725 | Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases(OPTIMAL) | unknown | Phase 2 | 110 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT04148898 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis(OWONBNSCLCLM) | unknown | Phase 2 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT04056572 | Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | unknown | Phase 2 | 135 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | unknown | Phase 1 / Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04131543 | Phase II Study With Cabozantinib in Patients With RET Positive NSCLC(CRETA) | unknown | Phase 2 | 25 | University of BolognaOTHER | 1 | Oct 18, 2019 | clinicaltrials |
| NCT04128800 | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT04124731 | Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) | unknown | Phase 2 | 98 | Shanghai Chest HospitalOTHER | 0 | Oct 11, 2019 | clinicaltrials |
| NCT04111913 | A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT04108013 | A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC | unknown | Phase 2 | 38 | Xuanwu Hospital, BeijingOTHER | 0 | Sep 27, 2019 | clinicaltrials |
| NCT04106180 | SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC | unknown | Phase 2 | 63 | Fudan UniversityOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT04054531 | Study of KN046 With Chemotherapy in First Line Advanced NSCLC | unknown | Phase 2 | 50 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | unknown | Phase 2 | 68 | Hunan Cancer HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT04029350 | Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M(ALTN-03) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04063462 | Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT03972189 | Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 111 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT03983928 | Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT04056949 | Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy | unknown | Phase 2 | 30 | Junling LiOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01823003 | Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases(sbrtlungfff) | unknown | Phase 2 | 67 | Institut Català d'OncologiaOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04023617 | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC | unknown | Phase 2 | 72 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT03987087 | A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC | unknown | Phase 2 | 68 | Guizhou Medical UniversityOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03726736 | Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC(ACWDVDFPTAN) | unknown | Phase 1 / Phase 2 | 97 | Yong FangOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03062800 | Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) | unknown | Phase 2 | 232 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03936621 | Efficacy and Safety of Omega 3 Fatty Acid Supplements on Heavy Smokers(Omega) | unknown | Phase 2 | 42 | British Columbia Cancer AgencyOTHER | 0 | May 7, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03647956 | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | unknown | Phase 2 | 40 | The University of Hong KongOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03911193 | CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation(CABinMET) | unknown | Phase 2 | 25 | Fondazione Ricerca TraslazionaleOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03903887 | A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT02605811 | Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer | unknown | Phase 2 | 426 | Guangzhou Medical UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jan 27, 2020source: clinicaltrials